| 0 (0%) | 11-11 19:25 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 184.15 | 1-year : | 215.09 |
| Resists | First : | 157.66 | Second : | 184.15 |
| Pivot price | 145.87  |
|||
| Supports | First : | 142.8 | Second : | 133.61 |
| MAs | MA(5) : | 151.64 |
MA(20) : | 144.37 |
| MA(100) : | 136.94 |
MA(250) : | 128.11 |
|
| MACD | MACD : | 2.6 |
Signal : | 1.9 |
| %K %D | K(14,3) : | 67.6 |
D(3) : | 76.3 |
| RSI | RSI(14): 54.3 |
|||
| 52-week | High : | 157.66 | Low : | 84.23 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ NBIX ] has closed below upper band by 43.1%. Bollinger Bands are 82.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 149.74 - 150.64 | 150.64 - 151.31 |
| Low: | 142.87 - 144.05 | 144.05 - 144.93 |
| Close: | 145.72 - 147.48 | 147.48 - 148.79 |
Tue, 11 Nov 2025
Neurocrine (Nasdaq: NBIX) to join Jefferies Nov. 18, Piper Sandler Dec. 2 webcasts - Stock Titan
Tue, 11 Nov 2025
Looking for a Growth Stock? 3 Reasons Why Neurocrine (NBIX) is a Solid Choice - sharewise.com
Tue, 11 Nov 2025
Neurocrine's Depression Drug Fails Phase 2 Goal But Shows Encouraging Safety Profile - Benzinga
Tue, 11 Nov 2025
Morgan Stanley Lowers Price Target for Neurocrine Biosciences (N - GuruFocus
Mon, 10 Nov 2025
How to build a custom watchlist for NBIX - Trade Analysis Report & Free Low Drawdown Momentum Trade Ideas - newser.com
Mon, 10 Nov 2025
Neurocrine Biosciences Provides Update on Phase 2 Study of NBI-1070770 in Adults with Major Depressive Disorder - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 99 (M) |
| Shares Float | 98 (M) |
| Held by Insiders | 1 (%) |
| Held by Institutions | 102.5 (%) |
| Shares Short | 4,370 (K) |
| Shares Short P.Month | 4,120 (K) |
| EPS | 3.38 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 27.21 |
| Profit Margin | 13.8 % |
| Operating Margin | 21.1 % |
| Return on Assets (ttm) | 8.6 % |
| Return on Equity (ttm) | 13.3 % |
| Qtrly Rev. Growth | 16.5 % |
| Gross Profit (p.s.) | 15.93 |
| Sales Per Share | 25.3 |
| EBITDA (p.s.) | 5.31 |
| Qtrly Earnings Growth | 68.3 % |
| Operating Cash Flow | 567 (M) |
| Levered Free Cash Flow | 367 (M) |
| PE Ratio | 43.57 |
| PEG Ratio | 0 |
| Price to Book value | 5.41 |
| Price to Sales | 5.82 |
| Price to Cash Flow | 25.75 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|